Skip to main content
Top
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat–cholesterol–sugar diet model in mice

Authors: Michal Ganz, Terence N Bukong, Timea Csak, Banishree Saha, Jin-Kyu Park, Aditya Ambade, Karen Kodys, Gyongyi Szabo

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is becoming a pandemic. While multiple ‘hits’ have been reported to contribute to NAFLD progression to non-alcoholic steatohepatitis (NASH), fibrosis and liver cancer, understanding the natural history of the specific molecular signals leading to hepatocyte damage, inflammation and fibrosis, is hampered by the lack of suitable animal models that reproduce disease progression in humans. The purpose of this study was first, to develop a mouse model that closely mimics progressive NAFLD covering the spectrum of immune, metabolic and histopathologic abnormalities present in human disease; and second, to characterize the temporal relationship between sterile/exogenous danger signals, inflammation, inflammasome activation and NAFLD progression.

Methods

Male C57Bl/6 mice were fed a high fat diet with high cholesterol and a high sugar supplement (HF–HC–HSD) for 8, 27, and 49 weeks and the extent of steatosis, liver inflammation, fibrosis and tumor development were evaluated at each time point.

Results

The HF–HC–HSD resulted in liver steatosis at 8 weeks, progressing to steatohepatitis and early fibrosis at 27 weeks, and steatohepatitis, fibrosis, and tumor development at 49 weeks compared to chow diet. Steatohepatitis was characterized by increased levels of MCP-1, TNFα, IL-1β and increased liver NASH histological score. We found increased serum levels of sterile danger signals, uric acid and HMGB1, as early as 8 weeks, while endotoxin and ATP levels increased only after 49 weeks. Increased levels of these sterile and microbial danger signals paralleled upregulation and activation of the multiprotein complex inflammasome. At 27, 49 weeks of HF–HC–HSD, activation of M1 macrophages and loss of M2 macrophages as well as liver fibrosis were present. Finally, similar to human NASH, liver tumors occurred in 41% of mice in the absence of cirrhosis and livers expressed increased p53 and detectable AFP.

Conclusions

HF–HC–HSD over 49 weeks induces the full spectrum of liver pathophysiologic changes that characterizes the progression of NAFLD in humans. NAFLD progression to NASH, fibrosis and liver tumor follows progressive accumulation of sterile and microbial danger signals, inflammasome activation, altered M1/M2 cell ratios that likely contribute to NASH progression and hepatic tumor formation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:766–781PubMedCrossRef Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:766–781PubMedCrossRef
2.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609PubMedCrossRef Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592–1609PubMedCrossRef
3.
go back to reference Tiniakos DG, Vos MB, Brunt EM (2010) Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5:145–171PubMedCrossRef Tiniakos DG, Vos MB, Brunt EM (2010) Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5:145–171PubMedCrossRef
4.
go back to reference Tarantino G, Savastano S, Colao A (2010) Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 16:4773–4783PubMedCentralPubMedCrossRef Tarantino G, Savastano S, Colao A (2010) Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 16:4773–4783PubMedCentralPubMedCrossRef
5.
6.
go back to reference Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N et al (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154–160PubMedCrossRef Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N et al (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154–160PubMedCrossRef
7.
go back to reference Corrado RL, Torres DM, Harrison SA (2014) Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 98:55–72PubMedCrossRef Corrado RL, Torres DM, Harrison SA (2014) Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 98:55–72PubMedCrossRef
8.
go back to reference Eguchi A, Povero D, Alkhouri N, Feldstein AE (2013) Novel therapeutic targets for nonalcoholic fatty liver disease. Exp Opin Ther Targets 17:773–779CrossRef Eguchi A, Povero D, Alkhouri N, Feldstein AE (2013) Novel therapeutic targets for nonalcoholic fatty liver disease. Exp Opin Ther Targets 17:773–779CrossRef
9.
go back to reference Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY et al (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59:969–974PubMedCrossRef Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY et al (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59:969–974PubMedCrossRef
10.
go back to reference Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285PubMedCrossRef Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285PubMedCrossRef
11.
go back to reference Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V (2011) Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 35:23–28PubMedCrossRef Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V (2011) Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 35:23–28PubMedCrossRef
12.
go back to reference Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:820–826PubMed Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C (2004) Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:820–826PubMed
13.
go back to reference Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98:2042–2047PubMedCrossRef Harrison SA, Torgerson S, Hayashi PH (2003) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98:2042–2047PubMedCrossRef
14.
go back to reference Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R et al (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41:751–757PubMedCrossRef Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R et al (2004) Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41:751–757PubMedCrossRef
15.
go back to reference Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28(Suppl 1):68–76PubMedCrossRef Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28(Suppl 1):68–76PubMedCrossRef
16.
go back to reference Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K et al (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72–76PubMedCrossRef Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K et al (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72–76PubMedCrossRef
17.
go back to reference White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10(1342–1359):e2PubMed White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10(1342–1359):e2PubMed
18.
go back to reference Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M et al (2012) Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 55:3382–3391PubMedCrossRef Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M et al (2012) Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 55:3382–3391PubMedCrossRef
19.
go back to reference Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V et al (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52:934–944PubMedCentralPubMedCrossRef Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V et al (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52:934–944PubMedCentralPubMedCrossRef
21.
go back to reference Ganz M, Csak T, Szabo G (2014) High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol 20:8525–8534PubMedCentralPubMedCrossRef Ganz M, Csak T, Szabo G (2014) High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol 20:8525–8534PubMedCentralPubMedCrossRef
22.
go back to reference Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:133–144PubMedCentralPubMedCrossRef Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54:133–144PubMedCentralPubMedCrossRef
23.
go back to reference Csak T, Pillai A, Ganz M, Lippai D, Petrasek J, Park J-K et al (2014) Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 34:1402–1413PubMedCentralPubMedCrossRef Csak T, Pillai A, Ganz M, Lippai D, Petrasek J, Park J-K et al (2014) Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 34:1402–1413PubMedCentralPubMedCrossRef
24.
go back to reference Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426PubMedCrossRef Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426PubMedCrossRef
25.
go back to reference Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V et al (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122:3476–3489PubMedCentralPubMedCrossRef Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V et al (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122:3476–3489PubMedCentralPubMedCrossRef
26.
go back to reference Lippai D, Bala S, Petrasek J, Csak T, Levin I, Kurt-Jones EA et al (2013) Alcohol-induced IL-1beta in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol 94:171–182PubMedCentralPubMedCrossRef Lippai D, Bala S, Petrasek J, Csak T, Levin I, Kurt-Jones EA et al (2013) Alcohol-induced IL-1beta in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol 94:171–182PubMedCentralPubMedCrossRef
27.
go back to reference Velayudham A, Hritz I, Dolganiuc A, Mandrekar P, Kurt-Jones E, Szabo G (2006) Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury. J Hepatol 45:813–824PubMedCrossRef Velayudham A, Hritz I, Dolganiuc A, Mandrekar P, Kurt-Jones E, Szabo G (2006) Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury. J Hepatol 45:813–824PubMedCrossRef
28.
go back to reference Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A et al (2012) NASH CRN: hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711–1721PubMedCentralPubMedCrossRef Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A et al (2012) NASH CRN: hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711–1721PubMedCentralPubMedCrossRef
29.
go back to reference Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M et al (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152:423–430PubMedCentralPubMed Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M et al (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152:423–430PubMedCentralPubMed
30.
go back to reference Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N et al (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416–426PubMedCrossRef Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N et al (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416–426PubMedCrossRef
31.
go back to reference Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161PubMedCrossRef Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161PubMedCrossRef
32.
34.
35.
go back to reference Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47:571–579PubMedCentralPubMedCrossRef Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47:571–579PubMedCentralPubMedCrossRef
36.
go back to reference Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287:40161–40172PubMedCentralPubMedCrossRef Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287:40161–40172PubMedCentralPubMedCrossRef
37.
38.
go back to reference Deng ZB, Liu Y, Liu C, Xiang X, Wang J, Cheng Z et al (2009) Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 50:1412–1420PubMedCentralPubMedCrossRef Deng ZB, Liu Y, Liu C, Xiang X, Wang J, Cheng Z et al (2009) Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 50:1412–1420PubMedCentralPubMedCrossRef
39.
go back to reference Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49:821–830PubMedCentralPubMedCrossRef Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49:821–830PubMedCentralPubMedCrossRef
42.
43.
go back to reference Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181–194PubMedCrossRef Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181–194PubMedCrossRef
44.
go back to reference Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21:491–497PubMedCrossRef Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21:491–497PubMedCrossRef
45.
go back to reference Bioulac-Sage P, Sempoux C, Possenti L, Frulio N, Laumonier H, Laurent C et al (2013) Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int J Hepatol 2013:253261PubMedCentralPubMed Bioulac-Sage P, Sempoux C, Possenti L, Frulio N, Laumonier H, Laurent C et al (2013) Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int J Hepatol 2013:253261PubMedCentralPubMed
46.
47.
go back to reference Sell S (2008) Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol 29:161–180PubMedCentralPubMedCrossRef Sell S (2008) Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol 29:161–180PubMedCentralPubMedCrossRef
48.
go back to reference Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J et al (2013) Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305:G483–G495PubMedCrossRef Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J et al (2013) Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305:G483–G495PubMedCrossRef
49.
go back to reference Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987–G995PubMedCentralPubMedCrossRef Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987–G995PubMedCentralPubMedCrossRef
50.
go back to reference Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A et al (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301:G825–G834PubMedCentralPubMedCrossRef Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A et al (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301:G825–G834PubMedCentralPubMedCrossRef
51.
go back to reference Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K et al (2011) Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 53:1526–1537PubMedCentralPubMedCrossRef Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K et al (2011) Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 53:1526–1537PubMedCentralPubMedCrossRef
52.
go back to reference Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54:2185–2197PubMedCentralPubMedCrossRef Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54:2185–2197PubMedCentralPubMedCrossRef
53.
go back to reference Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C et al (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 58:114–124PubMedCrossRef Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C et al (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 58:114–124PubMedCrossRef
54.
55.
go back to reference Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836–1846PubMedCrossRef Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836–1846PubMedCrossRef
56.
go back to reference Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F et al (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59:130–142PubMedCrossRef Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F et al (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59:130–142PubMedCrossRef
57.
go back to reference Iredale JP, Thompson A, Henderson NC (2013) Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 1832:876–883PubMedCrossRef Iredale JP, Thompson A, Henderson NC (2013) Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 1832:876–883PubMedCrossRef
58.
Metadata
Title
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat–cholesterol–sugar diet model in mice
Authors
Michal Ganz
Terence N Bukong
Timea Csak
Banishree Saha
Jin-Kyu Park
Aditya Ambade
Karen Kodys
Gyongyi Szabo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0552-7

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.